MedTrace Logo

Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

NCT03867201 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 557

Last updated 2025-10-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.

Conditions

Interventions

BIOLOGICAL

Erenumab

Administered by pre-filled syringe

OTHER

Placebo

Administered by pre-filled syringe

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2021-08-11
Completion
2024-04-30
FDA Drug
Yes

Countries

  • China
  • India
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03867201 on ClinicalTrials.gov